NUVB
The table below shows Nuvation Bio Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $83.23M | $13.12M | $4.83M | $3.08M | $727.00K | $1.44M |
| Cost of revenue | - | $3.35M | $2.58M | $2.09M | $1.51M | $1.35M |
| Gross profit | - | $9.77M | $2.26M | $990.00K | -$788.00K | $88.00K |
| R&D | $35.05M | $28.85M | $27.36M | $24.60M | $27.73M | $29.25M |
Nuvation Bio Inc. reported annual revenue of $62.90M for fiscal year 2025. That is up 699.0% from $7.87M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A | $38.31M | $37.36M | $38.48M | $35.39M | $19.58M | $16.16M |
| Operating income | $3.88M | -$56.43M | -$63.59M | -$59.00M | -$48.10M | -$470.38M |
| Income tax | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $5.40M | -$55.79M | -$59.01M | -$53.24M | -$41.21M | -$462.49M |
| EPS (diluted) | $0.01 | -$0.16 | -$0.17 | -$0.16 | -$0.15 | -$1.89 |